NOS2 and neoplasm: In addition, olaparib at sub-IC50 concentrations can block the expression of ARG-1, iNOS, and COX-2 and reduce the inhibitory function of MDSC, which is more effective in blocking tumor progression when used in conjunction with anti-PD-1 [99].